Hormonal contraception and migraine: Clinical considerations

Current Pain and Headache Reports

Volumn 16, Issue 5, 2012, Pages 461-466

  Faubion, Stephanie S ^a   Casey, Petra M ^b   Shuster, Lynne T ^c  

^a Women's Health Clinic   (United States)

^b MAYO CLINIC   (United States)

^c Office of Women's Health   (United States)

Author keywords

Combined hormonal contraceptive; Estrogen; Menstrual migraine; Migraine; Oral contraceptive; Stroke

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ANEMIA; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DYSMENORRHEA; ESTROGEN WITHDRAWAL HEADACHE; HEADACHE; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; HYPOTHALAMIC AMENORRHEA; LOW DRUG DOSE; MENSTRUAL CYCLE; MENSTRUAL MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PAIN; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; RISK FACTOR; VENOUS THROMBOEMBOLISM;

CHEMISTRY, PHARMACEUTICAL; CONTRACEPTIVES, ORAL, HORMONAL; ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; MIGRAINE DISORDERS; STROKE;

EID: 84870568144     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-012-0278-7     Document Type: Article

References (59)

1. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB, AMPP Advisory Group. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008;28:1170-8.
2. Edlow AG, Bartz D. Hormonal contraceptive options for women with headache: A review of the evidence. Rev Obstet Gynecol. 2010;3:55-65. This article provides a concise review of current recommendations from WHO, ACOG, and IHS regarding CHC use in women with headache and migraine.
3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPPAdvisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-9.
4. Calhoun A. Combined hormonal contraceptives: Is it time to reassess their role in migraine? Headache. 2012;52:648-60. The author highlights cumulative evidence supporting the use of CHCs for prevention of menstrual migraine as well as the lack of evidence that low-dose CHCs increase the stroke risk in non-smoking, normotensive women.
5. Shuster LT, Faubion SS, Sood R, Casey PM. Hormonal manipulation strategies in the management of menstrual migraine and other hormonally related headaches. Curr Neurol Neurosci Rep. 2011;11:131-8.
6. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Napp G. Migraine with aura and reproductive life events: A case control study. Cephalalgia. 2000;20:701-7.
7. Kvisvik EV, Stovner LJ, Helde G, Bovim G, Linde M. Headache and migraine during pregnancy and puerperium: The MIGRAstudy. J Headache Pain. 2011;12:443-51.
8. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: The role of hormones and their impact on vascular diseases. J Headache Pain. 2012;13:177-89. This article outlines current knowledge on the link of sex hormones to migraine, vascular effects of estrogen, and the association of migraine with vascular disease.
9. Wang SJ, Fuh JL, Lu SR, Juang KD, Wang PH. Migraine prevalence during menopausal transition. Headache. 2003;43:470-8.
10. Wöber C, Brannath W, Schmidt K, et al. Prospective analysis of factors related to migraine attacks: The PAMINA study. Cephalalgia. 2007;27:304-14.
11. Brandes JL. The influence of estrogen on migraine: A systematic review. JAMA. 2006;295:1824-30.
12. Loder E, Rizzoli P, Golub J. Hormonal management of migraine associated with menses and the menopause: A clinical review. Headache. 2007;47:329-40.
13. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67:2154-8.
14. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160.
15. Martin VT, Lipton RB. Epidemiology and biology of menstrual migraine. Headache. 2008;48 Suppl 3:S124-30.
16. Pinkerton JV, Guico-Pabia CJ, Taylor HS. Menstrual cycle-related exacerbation of disease. Am J Obstet Gynecol. 2010;202:221-31.
17. Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995;15:140-4.
18. Johannes CB, Linet MS, Stewart WF, Celentano DD, Lipton RB, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: A daily diary study. Neurology. 1995;45:1076-82.
19. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. Neurology. 2000;55:1517-23.
20. Loder EW. Menstrual migraine: Pathophysiology, diagnosis, and impact. Headache. 2006;46 Suppl 2:S55-60.
21. Pinkerman B, Holroyd K. Menstrual and nonmenstrual migraines differ in women with menstrually-related migraine. Cephalalgia. 2010;30:1187-94.
22. Hershey AD. Pediatric headache: Update on recent research. Headache. 2012;52:327-32.
23. Herzog AG. Neuroactive properties of reproductive steroids. Headache. 2007;47 Suppl 2:S68-78.
24. Gupta S, Mehrotra S, Villalón CM, Perusquía M, Saxena PR, MaassenVanDenBrink A. Potential role of female sex hormones in the pathophysiology of migraine. Pharmacol Ther. 2007;113:321-40.
25. Saleh TM, Connell BJ, Legge C, Cribb AE. Stroke-induced changes in estrogen release and neuronal activity in the parabrachial nucleus of the male rat. J Stroke Cerebrovasc Dis. 2004;13:24-34.
26. Hart EC, Charkoudian N, Miller VM. Sex, hormones and neuroeffector mechanisms. Acta Physiol (Oxf). 2011;203:155-65.
27. Calhoun A, Ford S. Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache. 2008;48:1186-93.
28. Peterlin BL, Calhoun AH, Balzac F. Chronic pain perspectives: Men, women, and migraine: The role of sex, hormones, obesity, and PTSD. J Fam Pract. 2012;61:S7-S11.
29. ACOG Practice Bulletin No. 110: Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010;115:206-18.
30. Hatcher R, Trussell J, Nelson A, Cates W, Stewart F, Kowal D. Contraceptive technology. 19th revised edition ed. New York: Ardent Media; 2007.
31. Casey PM, Cerhan JR, Pruthi S. Oral contraceptive use and risk of breast cancer. Mayo Clin Proc. 2008;83:86-90. quiz 90-1.
32. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010;82:221-9.
33. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261-6.
34. Calhoun AH. A novel specific prophylaxis for menstrualassociated migraine. South Med J. 2004;97:819-22.
35. LaGuardia KD, Fisher AC, Bainbridge JD, LoCoco JM, Friedman AJ. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril. 2005;83:1875-7.
36. Edelman A, Gallo MF, Nichols MD, Jensen JT, Schulz KF, Grimes DA. Continuous versus cyclic use of combined oral contraceptives for contraception: Systematic Cochrane review of randomized controlled trials. Hum Reprod. 2006;21:573-8.
37. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache. 2007;47:27-37.
38. De Leo V, Scolaro V, Musacchio MC, Di Sabatino A, Morgante G, Cianci A. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011;96:917-20.
39. Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing). Int J Womens Health. 2010;2:401-9.
40. Loder EW, Buse DC, Golub Jr. Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. Am J Obstet Gynecol. 2005;193:636-49.
41. Berger GS, Edelman DA, Talwar PP. The probability of side effects with ovral, norinyl 1/50 and norlestrin. Contraception. 1979;20:447-53.
42. Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia. 2000;20:155-6.
43. Loder EW, Buse DC, Golub Jr. Headache and combination estrogen-progestin oral contraceptives: Integrating evidence, guidelines, and clinical practice. Headache. 2005;45:224-31.
44. World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. World Health Organization 2010; 2010.
45. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA. 2000;284:72-8.
46. Kurth T, Schürks M, Logroscino G, Gaziano JM, Buring JE. Migraine, vascular risk, and cardiovascular events in women: Prospective cohort study. BMJ. 2008;337:a636.
47. MacGregor EA. Estrogen replacement and migraine. Maturitas. 2009;63:51-5.
48. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: An updated metaanalysis. Am J Med. 2010;123:612-24.
49. Chan WS, Ray J, Wai EK, et al. Risk of stroke in women exposed to low-dose oral contraceptives: A critical evaluation of the evidence. Arch Intern Med. 2004;164:741-7.
50. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: A pooled analysis of two US studies. Stroke. 1998;29:2277-84.
51. Schwartz SM, Siscovick DS, Longstreth Jr WT, et al. Use of lowdose oral contraceptives and stroke in young women. Ann Intern Med. 1997;127:596-603.
52. Poulter NR, Chang CL, FarleyTM,MarmotMG, Meirik O. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1999;354:301-2.
53. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109:339-46.
54. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010;81:408-13.
55. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2007;76:4-7.
56. Massiou H, MacGregor EA. Evolution and treatment of migraine with oral contraceptives. Cephalalgia. 2000;20:170-4.
57. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453-72.
58. Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke. 1997;28:1507-17.
59. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: Case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ. 1999;318:13-8.